Dr. Agarwal’s Health Care Ltd Q1FY26: India’s Largest Eye Hospital Chain with P/E 141, ROE 4.8% – Are Investors Blind or Just Wearing Rose-Colored Glasses?
1. At a Glance
Imagine paying ₹459 for a pair of “spectacles” where the lens is called P/E 141x and the frame is ROE 4.8%. That’s exactly what Dr. Agarwal’s Health Care is offering right now. With a market cap of ₹14,520 crore, this company has single-handedly claimed 25% of India’s eye-care service market, performing a jaw-dropping 1.15 million patient interactions and over 1.4 lakh surgeries in H1FY25. Revenues? ₹1,795 crore TTM. Profits? ₹103 crore. That’s a PAT margin of 5.9%, which is fine for a clinic but feels like a cataract blur for a “premium listed” healthcare chain. Yet, in the last three months, the stock gave a crisp +15% return, making many retail investors believe they now have 20/20 vision. Question is – is this stock a clear-eyed opportunity or are we all squinting too hard?
2. Introduction
India loves hospitals the way Bollywood loves sequels – too many, sometimes unnecessary, but they keep raking in money. But unlike Apollo or Fortis, Dr. Agarwal’s has positioned itself with laser-sharp focus – literally just eyes. No heart surgeries, no brain ops, just cataracts, LASIK, and the occasional fancy retinal transplant. And yet, this single-organ obsession has made it the largest eye-care chain in India.
It’s a classic story – started in 2010, backed by private equity money, grew faster than the number of “Buy 1 Get 1” eyeglass offers at Lenskart, and now sits with 165 facilities in India and 15 in Africa. Their revenue engine? A careful mix of 76% from mature hospitals (cash cows) and 24% from new facilities (cash-hungry toddlers). Add some optical sales and pharma products on the side, and voila – an eye-care empire.
But here’s the twist: despite commanding premium valuations (P/E > 2x industry median), the company’s ROE of 4.8% and ROCE of ~10% scream “work in progress.” It’s like buying an expensive pair of Ray-Bans only to realize they don’t block UV properly.
So, is this a case of investors seeing the future clearly, or are we staring at an overpriced mirage?
3. Business Model – WTF Do They Even Do?
Dr. Agarwal’s model is like a thali – Primary, Secondary, Tertiary, all plated together:
Primary Facilities – Your neighborhood clinic where doctors check eyes, write prescriptions, sell lenses, and sneak in a teleconsultation. Basically, the “starter pack.”
Secondary Facilities – Mid-sized surgical hubs where they handle cataracts (India’s favorite age-related problem). These are like “combo offers” – everything from glasses to surgeries.
Tertiary Facilities – The big boys. Super-specialty centers where they perform complicated retinal, corneal, and refractive surgeries. Also double up as Centers of Excellence for R&D and training.
Why is this smart? Because most facilities are leased, so they avoid heavy upfront capex. Think of it as “asset-light healthcare,” where instead of buying a hospital building, they rent and start cutting eyes open. The network design ensures patient flow moves upward – from basic checkups at a small center to premium surgeries at the flagship.
Oh, and don’t forget the side hustle – opticals (13% of H1FY25 revenue) and eye-care pharma (8%). Because why only bill for surgery when you can also sell overpriced anti-glare glasses and eye drops?
4. Financials Overview
Here’s how Q1FY26 stacked up:
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹487 Cr
₹403 Cr
₹460 Cr
20.8%
5.9%
EBITDA
₹128 Cr
₹104 Cr
₹131 Cr
23.1%
-2.3%
PAT
₹38 Cr
₹18 Cr
₹43 Cr
111%
-11.6%
EPS (₹)
0.95
0.45
1.03
111%
-7.8%
Annualized EPS = 0.95 × 4 = ₹3.8. CMP = ₹459 → P/E = 121x (not meaningful for traditional investors).
Commentary: The company looks like it just had LASIK – sharp revenue growth, but the profits fluctuate like a dilated pupil. And let’s be honest – a 121x P/E with 5% PAT margin is the stock market equivalent of paying Taj Mahal rates for a highway dhaba.
👉 Question for you: Would you ever pay 7.7x book value for a hospital that isn’t even giving free eye check-ups?
